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Newborn screening is the process of testing newborn
babies for inborn errors of metabolism that include dis-
orders of amino acids, organic acids, fatty acids and
urea cycle disorders.
Affected baby are usually normal at birth. Symptoms
develop after a latent period ranging from few hours to
many years. Many of these disease are potentially fatal
conditions and some are extremely rare, but the delay
or the lack of diagnosis and treatment can lead to devel-
opmental disability, mental retardation and premature
death [1,2]
A significant percentage of these conditions (approxi-
mately 30-40%) is susceptible to dietary therapy, while
in the remaining cases have been proposed various
treatment strategies such as enzyme replacement ther-
apy (ERT), vitamin supplementation, organ transplants,
in addition to the use of new drugs with specific action.
The neonatal screening by tandem mass spectrometry
(expanded newborn screening) allows the early detection
of about 50 of these congenital disorders.
The advantages of this method consist in the speed of
execution (1-2 minutes for each analysis), the ability to
examine numerous analytes in a single spot of blood,
the ability to recognize variants “mild” of numerous dis-
eases and then to have updated epidemiological data, a
favourable cost effectiveness ratio.
Among the disadvantages we must mention the false
positive and false negatives. The first become negligible
if the sampling is performed correctly and if the cut-off
values of various analytes are re-evaluated periodically,
the latter can be attributed to technical errors (sampling
time, cut-off or laboratory errors) or to the fact that
some of these diseases can not yet recognized by the
tandem mass spectrometry [3]
Technological and therapeutic advances during the past
5-10 years have made possible a great expansion of neona-
tal screening, however, views about which disorder should
be included ranging from the five disorders screened in
UK to more than 50 recommended in USA [4].
In Sicily, a Regional project, has allowed us to begin the
expanded newborn screening, dividing the Region into
two areas, east and west, the first assigned to the “Centre
for the prevention, diagnosis and treatment of congenital
metabolic diseases” of Catania and, the other, to the
“Screening Centre” of Palermo. The project includes
screening for 30 diseases.
There is a large debate in the scientific literature on the
opportunity to introduce neonatal screening for other
congenital diseases such as, for example, the lysosomal
storage diseases [4-7].
Published: 11 August 2014
References
1. Sharrad M, Pollit R: Metabolic screening in children: newborn screening
for metabolic diseases past, present and future. Pediatrics and Child
Health 2007, 17:273-28.
2. Petros M: Revisiting the Wilson-Jungner criteria: how can supplemental
criteria guide public health area in the era of genetic screening? Genet
Med 2012, 162:156-159.
3. Sorge G: La Tandem-mass (screening neonatale allargato). Proceedings
XXXVI Congresso Regionale SIP, XI Congresso Regionale SIN, IV Congresso
Regionale SIMEUP Palermo; 2007, 83-87.
4. Lehotay DC, Hall P, Lepage J, Eichhorst JC, Etter MI, Greenberg CR: LC-MS/
MS progress in newborn screening. Clinical Biochemistry 2011, 44:21-31.
5. Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A,
Herkner KR, Streubel B, Kasper DC: Neonatal screening for lysosomal
storage disorders: feasibility and incidence from a nationwide study in
Austria. Lancet 2012, 379:335-341.
6. Orsini JJ, Martin MM, Showers AL, Bodamer OA, Zhang XK, Gelb MH,
Caggana M: Lysosomal storage disorders 4+1 multiplex assay for
newborn screening using tandem mass spectrometry: Application to a
small-scale population study for five lysosomal storage disorders. Clinica
Chmica Acta 2012, 413:1270-1273.
7. Scott CR, Elliot S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH,
Turecek F: Identification of infants at risk for developing Fabry, Pompe,
or Mucopolysaccharidosis-I from newborn blood spots by tandem mass
spectrometry. J Pediatr 2013, 163:498-503.
Dipartimento di Scienze Mediche e Pediatriche, Unità Operativa Complessa
di Clinica Pediatrica, Centro di Riferimento Regionale per la prevenzione, la
diagnosi e la cura delle malattie metaboliche congenite dell’infanzia,
Università di Catania, Italy
Sorge Italian Journal of Pediatrics 2014, 40(Suppl 1):A63
http://www.ijponline.net/content/40/S1/A63
© 2014 Sorge; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
doi:10.1186/1824-7288-40-S1-A63
Cite this article as: Sorge: The metabolic screening today. Italian Journal
of Pediatrics 2014 40(Suppl 1):A63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sorge Italian Journal of Pediatrics 2014, 40(Suppl 1):A63
http://www.ijponline.net/content/40/S1/A63
Page 2 of 2
